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Background: MicroRNA-224 has been proven dysregulated in some human malignancies and correlated with
tumor progression. However, its expression and clinical significance in non–small cell lung cancer (NSCLC) is still
unclear. Thus, the aim of this study was to explore the effects of miR-224 in NSCLC tumorigenesis and development.
Methods: Using real-time quantitative RT-PCR, we detected miR-224 expression in NSCLC cell lines and primary tumor
tissues. The association of miR-224 expression with clinicopathological factors and prognosis was also statistically
analyzed. MTT, flow cytometric, Transwell invasion and migration assays, and scratch migration assay were used to test
the proliferation, apoptosis, invasion, and migration of NSCLC cells after miR-224 mimics transfection.
Results: MiR-224 expression levels were significantly down-regulated in NSCLC compared to the corresponding
noncancerous lung tissues (P <0.001). In addition, decreased miR-224 expression was significantly associated with
lymph node metastasis (P = 0.002), advanced TNM stage (P <0.001), and shorter overall survival (P <0.001). Multivariate
regression analysis corroborated that down-regulation of miR-224 was an independent unfavourable prognostic factor
for patients with NSCLC. Furthermore, transfection of miR-224 mimics in NSCLC A549 cells was able to reduce cell
proliferation, invasion, and migration, and promote cell apoptosis.
Conclusions: These findings indicate that miR-224 may act not only as a novel diagnostic and prognostic marker, but
also as a potential target for miR-based therapy of NSCLC.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_198
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Lung cancer is the leading cause of cancer related deaths
worldwide [1]. Despite advances in the fields of oncology
and surgery, the prognosis of lung cancer has not im-
proved significantly over several decades [2]. Non–small
cell lung cancer (NSCLC) is the predominant group of lung
cancer. To date, the highly complex molecular mechanisms
underlying NSCLC carcinogenesis and progression remain
poorly understood, and no appropriate biomarker exists to
detect NSCLC at early stages. Therefore, it is necessary to
search novel markers for NSCLC, which can accurately
identify biological characteristics of tumors, improve thera-
peutic strategies, and predict clinical outcome.* Correspondence: manuzhudan@163.com
Department of Respiratory Medicine, Jinhua Municipal Central Hospital,
Jinhua 321000, P.R. China
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unless otherwise stated.MicroRNAs (miRNAs) are single-stranded, small non-
coding RNAs with 18–25 nucleotides in length [3]. They
can negatively regulate gene expression through base-
pairing to the 3′ untranslational region (3′UTR) of target
messenger RNA (mRNA), resulting in translation inhib-
ition or mRNA degradation [4,5]. Beyond the involvement
in diverse biological processes, including cell growth, apop-
tosis, development, differentiation and endocrine homeo-
stasis [6], emerging evidence strongly suggests that the
deregulation or dysfunction of miRNAs contributes to hu-
man carcinogenesis and cancer progression [7-9]. miRNAs
can function as either oncogenes or tumor suppressors ac-
cording to the roles of their target genes. In terms of
NSCLC, in vitro functional assays showed that both miR-
31 and miR-196 promote the proliferation, invasion, and
migration of cancer cells [10,11]. Clinical analysis demon-
strated that decreased miR-375 and increased miRNA-21. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Correlation between miR-224 expression and







Low (n, %) High (n, %)
Age
<60 58 34 (58.6%) 24 (41.4%) 0.094
≥60 57 24 (42.1%) 33 (57.9%)
Gender
Male 77 40 (51.9%) 37 (48.1%) 0.695
Female 38 18 (47.4%) 20 (52.6%)
Smoking status
Smoking 68 38 (55.9%) 30 (44.1%) 0.591
No smoking 47 20 (42.6%) 27 (57.4%)
Smoking intensity
(for smokers)
<30 pack years 38 17 (44.7%) 21 (55.3%) 0.484
≥30 pack years 30 17 (56.7%) 13 (43.3%)
Occupational exposure
Yes 32 14 (43.8%) 18 (56.2%) 0.411
No 83 44 (53.0%) 39 (47.0%)
Histological type
Squamous cell carcinoma 40 23 (57.5%) 17 (42.5%)
Adenocarcinoma 61 26 (42.6%) 35 (57.4%) 0.186
Others 14 9 (64.3%) 5 (35.7%)
Histological grade
G1 + G2 61 27 (44.3%) 34 (55.7%) 0.192
G3 54 31 (57.4%) 23 (42.6%)
T classification
T1+2 77 36 (46.8%) 41 (53.2%) 0.323
T3 38 22 (57.9%) 16 (42.1%)
N classification
Positive 80 48 (60.0%) 32 (40.0%) 0.002
Negative 35 10 (28.6%) 25 (71.4%)
TNM stage
I + II 69 25 (36.2%) 44 (63.8%) <0.001
III 46 33 (71.7%) 13 (28.3%)
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vanced clinical stage and poor prognosis [12,13]. Further-
more, Bian et al. reported that upregulation of miR-451
sensitized NSCLC A549 cells to cisplatin [14]. Wang et al.
found that knock-down of miRNA-21 promoted the radio-
sensitivity of A549 cells [13]. These findings indicate that
miRNAs may act not only as diagnostic and prognostic
markers, but also as potential therapeutic targets of human
NSCLC.
One of the cancer-related miRNAs is miR-224. Aber-
rant expression of miR-224 in human malignancies has
been demonstrated to play various roles in tumorigen-
esis. The expression level of miRNA-224 was downregu-
lated in oral cancer [15], ovarian cancer [16], prostate
cancer [17], malignant giant cell tumor [18], and glio-
blastoma [19]; while it was upregulated and functioned
as an oncogene in hepatocellular carcinoma [20], clear
cell renal cell carcinoma [21], pancreatic cancer [22],
and cervical cancer [23]. Notably, a previous study by
Yanaihara et al. detected decreased miR-224 levels in hu-
man lung cancer tissues using miRNA microarray ana-
lysis [24]. However, currently, little is known about the
links of miR-224 dysregulation to clinicopathological
characteristics of NSCLC, and the functional attributes
of miR-224 associated with NSCLC progression have not
been experimentally established.
In the present study, we examined miR-224 expression
in NSCLC tissues and cell lines using real-time PCR.
The association of miR-224 levels with clinicopathologic
features and prognosis was also analyzed. Furthermore,
we investigated the effects of miR-224 on proliferation,
apoptosis, invasion and migration of NSCLC cells.
Methods
Patients and tissue samples
This study was approved by the Research Ethics
Committee of Jinhua Municipal Central Hospital (Jinhua,
Zhejiang province, People’s Republic of China). Written
informed consent was obtained from all of the patients.
All specimens were handled and made anonymous ac-
cording to the ethical and legal standards.
One hundred and fifteen pairs of primary NSCLC and
adjacent noncancerous tissues (>2 cm from the cancer
tissue, in the same lobe) were collected at the time of
surgery from patients who underwent surgical resection
at Jinhua Municipal Central Hospital from January 1, 2007
to December 30, 2009. There were 77 men (67%) and 38
women (33%) with median age of 60 years at the time of
diagnosis. The selection criteria were as follows: (1) patho-
logically confirmed patients with NSCLC; (2) no evidence
of distant metastases. Patients were excluded if they had a
previous or secondary malignancy, and/or had undergone
chemotherapy, radiation therapy or immunotherapy be-
fore surgery. All tissues were immediately frozen in liquidnitrogen and stored at −80°C until use. Clinicopathologi-
cal information was shown in Table 1. Smoking intensity
was evaluated according to pack years, which were calcu-
lated by multiplying the number of cigarette packs (20 cig-
arettes per pack) smoked per day by the number of years
of smoking. High risk jobs meant occupational exposure
to carcinogens such as asbestos and silica dust. Clinical
follow-up was available for all patients. Overall survival
(OS) was defined as the time from primary surgery to
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Cell lines and culture conditions
Four NSCLC cell lines (A549, H460, 95D, and H358) and
a normal human bronchial epithelial cell line (16HBE)
were purchased from the Institute of Biochemistry and
Cell Biology of the Chinese Academy of Sciences
(Shanghai, China). Cells were cultured in RPMI 1640
medium (Invitrogen, Gaithersburg, MD, USA) supple-
mented with 10% fetal bovine serum (10% FBS), 100 U/ml
penicillin, and 100 ug/ml streptomycin in humidified air
at 37°C with 5% CO2.
RNA extraction and quantitative real-time PCR
Total RNA was isolated using TRIzol® reagent (Invitrogen
Corp, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. Reverse transcription reaction was
carried out starting from 100 ng of total RNA using the
looped primers. Real-time PCR was performed using the
standard Taqman MicroRNA assays protocol on ABI7500
real-time PCR detection system with cycling conditions of
95°C for 10 min, followed by 40 cycles of 95°C for 15 s
and 60°C for 60 s. U6 small nuclear RNA was used as an
internal control. The PCR primers for mature miR-224
or U6 were designed as follows: miR-224 forward, 5′-
CACTAGTGGTTCCGTTTAGTAG -3′ and reverse, 5′- TT
GTAGTCACTAGGGCACC -3′. U6 forward, 5′- CTCGC
TTCGGCAGCACA-3′ and reverse, 5′-AACGCTTCACG
AATTTGCGT-3′. The threshold cycle (Ct) was defined as
the fractional cycle number at which the fluorescence passed
the fixed threshold. Each sample was measured in triplicate,
and the relative amount of miR-224 to U6 was calculated
using the equation 2−ΔCt, where ΔCT= (CTmiR-224 - CTU6).
Cell transfection
For RNA transfection, the cells were seeded into each well
of 24-well plate and incubated overnight, then transfected
with either miR-224 mimics (GenePharma, Shanghai,
China) or negative control (NC) RNA-oligonucleotides
(GenePharma) using Lipofectamine 2000 (Invitrogen,
California, USA) in accordance with the manufacturer’s
procedure. The transfection efficiency of miR-224 mimics
was confirmed by real-time PCR analysis.
MTT assay
Cells were seeded into 96-well culture plates at a density
of 2,000 cells in 200 uL/well and incubated at 37°C after
transfection. 100 uL of MTT solution (0.5 mg/mL;
Sigma, USA) was added to each well, and the cells were
incubated for another 4 hours. Then the medium was
replaced with 150 uL of DMSO. Spectrometric absorb-
ance at 490 nm was measured using a microplate reader.Cell proliferation was assessed daily for 4 consecutive
days, and the MTT assay was repeated 3 times.
Detection of apoptosis by flow cytometry
Apoptosis was detected by flow cytometric analysis.
Briefly, the cells were washed and resuspended at a con-
centration of 1 × 106 cells/mL. Then, the cells were stained
with Annexin V and propidium iodide (PI), using the
Annexin V apoptosis detection kit. After incubation at
room temperature in the dark for 15 min, the cell apop-
tosis was analyzed on a FACSCalibur (Becton, Dickinson
and Company, San Jose, CA).
Transwell migration and invasion assays
The migration and invasion assays were performed using
24-well transwell chambers (8 μm; Corning). For the mi-
gration assay, tumor cells were resuspended in serum-free
RPMI-1640 medium and 2 × 105 cells were seeded into
the upper chambers. 0.5 mL RPMI-1640 containing 10%
FBS was added to the bottom chambers. Following a 24
h-incubation, cells on the upper surface of the membrane
were scrubbed off, and the migrated cells were fixed with
95% ethanol, stained with 0.1% crystal violet, and counted
under a light microscope. The invasion assay protocol was
similar to that of the migration assay except that the upper
chambers were first covered with 1 mg/mL Matrigel.
Scratch migration assay
Scratch migration assay was also performed to confirm
the influence of miR-224 on NSCLC cell migration.
When the cells transfected with miR-224 mimics or NC
were grown to confluence, a scratch in the cell monolayer
was made with a cell scratch spatula. After the cells were
incubated under standard conditions for 24 h, pictures of
the scratches were taken by using a digital camera system
coupled with a microscope.
Statistics
Statistical analyses were carried out using SPSS software
(version 16.0, SPSS Inc, IL, USA). Data were expressed
as mean ± standard deviation (SD). The differences be-
tween groups were analyzed using the Student’s t-test,
chi-square test or Fisher’s exact test. Patient survival
curves were estimated by the Kaplan-Meier method.
The joint effect of covariables was examined using the
Cox Proportional Hazard Regression Model. All tests were
two-tailed, and the significance level was set at P <0.05.
Results
Decreased expression of miR-224 in NSCLC tumor
samples and cell lines
The expression levels of miR-224 in primary NSCLC,
corresponding adjacent normal lung tissues, human
NSCLC cell lines A549, H460, 95D, and H358, and
Table 2 Univariate and multivariate analysis of overall
survival in 115 patients with non–small cell lung cancer
Figure 1 Expression of miR-224 in non–small cell lung cancer (NSCLC) tissues and cell lines. The expression levels were measured by
qRT-PCR. A MiR-224 expression was significantly lower in NSCLC tissues than in the corresponding non-cancerous tissues. MiR-224 expression
levels were calculated by the 2−ΔCt method and normalized to U6 small nuclear RNA. B miR-224 expression was down-regulated in NSCLC cell
lines A549, H460, 95D, and H358, compared to normal human bronchial epithelial cell line 16HBE.
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were detected by qRT-PCR and normalized to U6 small
nuclear RNA. As in Figure 1A, the results showed that
the expression levels of miR-224 were significantly
lower in NSCLC specimens (mean ± SD: 8.1 ± 2.1) than
those in the corresponding adjacent non-cancerous tis-
sues (mean ± SD: 19.5 ± 3.9; P <0.001). The miR-224 ex-
pression in four NSCLC cell lines was also clearly
downregulated (Figure 1B). The A549 cell line, which
possessed the lowest levels of miR-224 expression









<60 vs. ≥60 0.62 —— ——
Gender
Male vs. Female 0.45 —— ——miR-224 expression and clinicopathologic features in
NSCLC
The associations of miR-224 expression with various
clinicopathological parameters of NSCLC tissues were
summarized in Table 1. Using the median miR-224Figure 2 Overall survival curves for two groups defined by low
and high expression of miR-224 in patients with non–small cell
lung cancer (NSCLC). Low miR-224 expression levels were significantly
associated with poor outcome (P <0.001, log-rank test).expression in all 115 NSCLC patients as a cutoff, the
patients were divided into high miR-224 expression
group and low miR-224 expression group. As shown in
Table 1, miR-224 expression level was lower in samples
with lymph node metastasis (P = 0.002) and advanced
TNM stage (P <0.001). No significant difference was
observed between miR-224 expression and patients’










(G1 + G2) vs G3 0.19 —— ——
T classification
T1+2 vs T3 0.16 —— ——
N classification
Positive vs negative 0.022 0.032 5.156
TNM stage
I-II vs III < 0.001 0.008 9.328
MiR-224 expression
High vs low < 0.001 0.015 7.514
Figure 3 (See legend on next page.)
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Figure 3 Effects of miR-224 mimics transfection on cell proliferation, apoptosis, invasion, and migration of A549 cells. (A) The expression
level of miR-224 in miR-224 mimics transfected cells was significantly higher compared with NC transfected cells. qRT-PCR was done to detect the
expression of miR-224. U6 RNA was used as an internal control. ***p <0.001. (B) Cell proliferation was measured by MTT assays in A549 cells transfected
with miR-224 mimics or negative control. Data represent the mean ± SD of the experiments performed in triplicate. **p <0.01. (C) Apoptosis of A549
cells was detected by flow cytometric analysis after transfection with miR-224 mimics or negative control. (D, E) miR-224 suppressed A549 cell invasion
and migration in vitro. The Matrigel invasion and migration assays showed that the number of invaded or migrated cells was significantly lower in the
miR-224-transfected group than in the NC-transfected group. **p <0.01. (F) Scratch migration assay confirmed the inhibitory effect of miR-224 on A549
cell migration.
Zhu et al. Diagnostic Pathology 2014, 9:198 Page 6 of 8
http://www.diagnosticpathology.org/content/9/1/198Down-regulation of miR-224 confers poor prognosis in
patients with NSCLC
We further evaluated whether miR-224 expression had
prognostic potential for OS of NSCLC patients. Using the
Kaplan–Meier method and logrank test, we found that the
survival rate of patients with high miRNA-224 expression
was higher than that of patients with low miRNA-224 ex-
pression (P <0.001; Figure 2). Besides, the survival benefits
were also found in those with negative N classification
(P = 0.022) and early TNM stage (P <0.001; Table 2).
Multivariate Cox regression analysis enrolling above-
mentioned significant parameters revealed that miR-224
expression (relative risk [RR] 7.514; P = 0.015), lymph
node metastasis (RR 5.156; P = 0.032), and TNM stage
(RR 9.328; P = 0.008) were independent prognostic
markers for OS of NSCLC patients (Table 2).
Effects of miR-224 on the proliferation, apoptosis,
invasion and migration of A549 cells
At last, we assessed the biological role of miR-224 in
A549 cells. As shown in Figure 3A, the expression level
of miR-224 in miR-224 mimics transfected cells was
significantly higher compared with NC transfected cells
(P <0.001). MTT assay showed that cell proliferation
was significantly impaired after miR-224 mimics transfec-
tion (Figure 3B). We also observed promoted cell apop-
tosis in miR-224 mimics transfected cells (Figure 3C).
Transwell invasion and migration assays were per-
formed to investigate whether miR-224 had a direct in-
fluence on A549 cell migration and invasion. As shown
in Figure 3D and E, up-regulation of miR-224 impeded
cell invasion/migration compared with control. Scratch
migration assay also confirmed the inhibitory effect of
miR-224 on A549 cell migration (Figure 3F).
Discussion
Lung cancer is a malignant tumor that seriously
threatens human health. It is of great significance to in-
vestigate molecular and cellular mechanisms of lung
cancer, and to identify novel genetic or protein markers
for accurate diagnosis and prediction of prognosis. In
the current study, we firstly observed that miR-224 was
down-regulated in NSCLC compared with adjacent non-
cancerous tissues. Then, decreased miR-224 expressionwas significantly correlated with aggressive clinicopatho-
logical features. Moreover, the Kaplan-Meier analysis
revealed that NSCLC patients with low miR-224 ex-
pression tend to have shorter OS. Multivariate Cox re-
gression analysis identified miR-224 expression level as an
independent prognostic factor for OS of NSCLC patients.
Finally, in vitro functional assays demonstrated that up-
regulation of miR-224 expression in A549 cells was able
to reduce cell proliferation, invasion, and migration, and
promote cell apoptosis. To the authors’ knowledge, this is
the first report regarding the clinical significance and
functional attributes of miR-224 in NSCLC.
MiR-224 has been shown its tumor-suppressor func-
tions in several cancers. Upraity et al. reported that miR-
224 was downregulated in glioblastoma tumor tissues
and cell lines [19]. Upregulation of miR-224 was found
to reduce clonogenic potential of glioblastoma cells and
enhance radiation sensitivity. Lower miR-224 expression
showed significant correlation with poorer survival. Lin
et al. revealed that reduced expression of miR-224 in
prostate cancer was associated with metastasis, high
PSA level, high Gleason scores, and poor biochemical
recurrence-free survival [25]. Forced expression of miR-
224 suppressed prostate cancer cell proliferation, inva-
sion and migration, and promoted cell apoptosis [17,25].
MiR-224 expression has also been found to correlate in-
versely with tumor stage and lymph node metastasis as
well as survival times in colorectal cancer patients [26].
Metastatic colorectal cancer cells (SW620) transfected
with miR-224 mimics had reduced migration and motil-
ity in vitro and formed smaller tumors with fewer metas-
tases in mice model. Furthermore, miR-224 upregulation
enhances radiation sensitivity of medulloblastoma cells
[27], and a 13-gene miRNA signature including increased
miR-224 levels would predict good response of lung can-
cer cells to EGFR inhibitor erlotinib treatment [28].
In contrast to the tumor-suppressive properties men-
tioned above, miR-224 also acts as an oncogene in some
other cancers. Overexpression of miR-224 in human he-
patocellular carcinoma was associated with promoted
cell migration and invasion and poorer patient survival
[20,29]. In cervical cancer, miR-224 expression was sig-
nificantly higher in the cancerous tissues of patients with
poor differentiation, lymph node metastasis, vascular
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survival [23]. In addition, the upregulation of miR-224
was also shown in breast cancer [30], clear cell renal cell
carcinoma [31], pancreatic ductal adenocarcinoma [22],
and bladder cancer [32]. So, miR-224 plays diverse func-
tions in cancer pathogenesis and progression, and the
role of miR-224 should be tumor specific and possibly
dependent on its targets in different cancer types.
Previous research has identified many oncogenes or
tumor suppressor genes as direct targets of miR-224, such
as apoptosis inhibitor 5 (API5) [19], Homeobox D10
(HOXD10) [20], SMAD family member 4 (SMAD4) [33],
SMAD family member 5 (SMAD5 [18], sarcolemma-
associated protein (SLMAP) [18], Type 1 iodothyronine
deiodinase (DIO1) [21], tumour protein D52 (TPD52)
[17], tribbles homolog 1 (TRIB1) [25], chemokine (C-X-C
motif) receptor 4 (CXCR4) [34], hypoxia-inducible factor
1 (HIF1A) [35], Raf kinase inhibitor protein (RKIP) [30],
and cell division control protein 42 (CDC42) [36]. It is now
clear that miRNAs execute their oncogenic or tumor sup-
pressive functions by regulating the expression of target
genes. However, an average miRNA can have more than
100 targets [37], and more than one miRNA can converge
on a single transcript target [38]. Therefore, the potential
regulatory circuitry afforded by miR-224 is enormous, and
the accurate mechanisms on how miR-224 influences
NSCLC progression need further clarification.
Conclusion
In conclusion, our results revealed that miRNA-224 was
down-regulated in NSCLC cell lines and clinical sam-
ples. Decreased miRNA-224 expression was associated
with aggressive progression and poor prognosis. Re-
stored miR-224 expression in A549 cells exhibited anti-
tumor effects in vitro. These findings demonstrate that
miRNA-224 could not only be useful as a novel bio-
marker but also serve as a potential target for gene ther-
apy of NSCLC.
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